.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,053,065

« Back to Dashboard

Details for Patent: 7,053,065

Title:Vitamin B12 and pemetrexed disodium combination therapies
Abstract: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Inventor(s): Niyikiza; Clet (Indianapolis, IN), Paoletti; Paolo (Indianapolis, IN), Rusthoven; James Jacob (Ancaster, CA)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Jun 15, 2001
Application Number:10/297,821
Claims:1. A method of reducing toxicity associated with the administration of pemetrexed disodium comprising administering an effective amount of pemetrexed disodium in combination with about 500 .mu.g to about 1500 .mu.g of a methylmalonic acid lowering agent selected from the group consisting of vitamin B.sub.12, hydroxocobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-chlorocobalamin perchlorate, azidocobalamin, chlorocobalamin, cobalamin, and cyanocobalamin wherein the methylmalonic acid lowering agent is administered from about 1 to about 3 weeks prior to the first administration of pemetrexed disodium and the methylmalonic acid lowering agent administration is repeated from about every 6 weeks to about every 12 weeks.

2. The method of claim 1 wherein about 1000 .mu.g of the methylmalonic acid lowering agent is administered.

3. The method of claim 1 or 2 wherein the methylmalonic acid lowering agent is administered by an intramuscular injection, orally, w as a parenteral.

4. The method of claim 3 wherein the methylmalonic acid lowering agent is administered by an intramuscular injection.

5. The method of claim 3 wherein the methylmalonic acid lowering agent is administered orally.

6. A method of reducing toxicity associated with the administration of pemetrexed disodium comprising administering an effective amount of pemetrexed disodium in combination with about 500 .mu.g to about 1500 .mu.g of a methylmalonic acid lowering agent selected from the group consisting of vitamin B.sub.12, hydroxocobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-chlorocobalamin perchlorate, azidocobalamin, chlorocobalamin, cobalamin, and cyanocobalamin wherein the methylmalonic acid lowering agent is administered by an intramuscular injection and the metthylmalonic acid lowering agent is administered from about 1 to about 3 weeks prior to the first administration of pemetrexed disodium and the methylmalonic acid lowering agent administration is repeated from about every 6 weeks to about every 12 weeks.

7. A method of reducing toxicity associated with the administration of pemetrexed disodium comprising administexing an effective amount of pemetrexed disodium in combination with about 500 .mu.g to about 1500 .mu.g of a methylmalonic acid lowering agent selected from the group consisting of vitamin B.sub.12, hydroxocobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-chlorocobalamin perchlorate, azidocobalamin, chlorocobalamin, cobalamin, and cyanocobalamin wherein the treatment with the methylmalomic acid lowering agent is administered by an intramuscular injection or orally and is repeated from about every 24 hours to about every 1680 hours, until treatment with pemetrexed disodium has ended.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc